Ranbaxy/GSK Partnership Yields First Drug Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Ranbaxy will develop a respiratory disease candidate through proof of concept under an expanded discovery agreement inked with GSK in February.
You may also be interested in...
Ranbaxy Delays Spin Off Of R&D Unit Until Later This Year
Indian firm reports 17.95 billion rupees ($460 million) in sales, up from 17.08 billion rupees a year ago, with a 2012 goal of being a top-five generics company.
Ranbaxy Delays Spin Off Of R&D Unit Until Later This Year
Indian firm reports 17.95 billion rupees ($460 million) in sales, up from 17.08 billion rupees a year ago, with a 2012 goal of being a top-five generics company.
Ranbaxy Board Approves Spin-off Of Drug Discovery Company
Ranbaxy Laboratories is moving to "de-merge" its drug discovery activities into a separate company with dedicated resources, the firm announced Oct. 18
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: